Prospectus approved

Posted on Sep 17, 2018

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE […]

Rights issue approved by the extraordinary general meeting

Posted on Sep 14, 2018

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE […]

Second quarter and first half-year 2018 results

Posted on Aug 30, 2018

Oslo (Norway), 30 August 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its interim second quarter and first half-year 2018 result. Please find enclosed the report and presentation. The proposed fully underwritten rights issue of NOK 360 million provides PCI Biotech with the funds needed for the pivotal fimaCHEM study […]